当前位置: X-MOL 学术J. Am. Coll. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
New Valves May Overcome Weaknesses of Transcatheter Aortic Valve Replacement ∗
Journal of the American College of Cardiology ( IF 24.0 ) Pub Date : 2017-12-01 , DOI: 10.1016/j.jacc.2017.10.074
Luis Nombela-Franco

SEE PAGE 3127 T ranscatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic valve stenosis, especially in elderly patients with moderate to high surgical risk. The initial 1-year mortality rate of w30% has continuously decreased to w7% in recent randomized trials and registries (1,2). Several factors, such as better patient selection, increased operator experience, technical improvements in delivery systems, and newer generation transcatheter heart valves (THV) have contributed to better outcomes. However, there is still room for improvement, given that rates of vascular complication, paravalvular leakage (PVL), and permanent pacemaker implantation (PPI) continue to be higher than that of surgery (1,2). The CENTERA valve (Edwards Lifesciences, Irvine, California) is the new generation self-expandable (SE)-THV from the Edwards family that incorporates some interesting technical advantages (3). The stent frame is available in 3 sizes (23, 26, and 29 mm at waist level) and incorporates 3 bovine pericardial leaflets in an annular position. The shape and design of the nitinol frame facilitates centering and seating the valve within the annulus. Additionally, its short length (the shortest frame compared with those of other SE systems) ensures limited extension in the ascending aorta and minimal protrusion of the flared inflow portion into the left ventricular outflow tract (LVOT). The valve is pre-attached to a motorized delivery system (compatible with a 14-F expandable

中文翻译:

新瓣膜可克服经导管主动脉瓣置换术的弱点 ∗

参见第 3127 页 经导管主动脉瓣置换术 (TAVR) 彻底改变了严重主动脉瓣狭窄的治疗方法,尤其是在手术风险中等到高的老年患者中。在最近的随机试验和注册研究中,初始 1 年死亡率 w30% 持续下降至 w7% (1,2)。几个因素,例如更好的患者选择、增加的操作员经验、输送系统的技术改进以及新一代经导管心脏瓣膜 (THV),都有助于获得更好的结果。然而,鉴于血管并发症、瓣周漏 (PVL) 和永久起搏器植入 (PPI) 的发生率继续高于手术 (1,2),因此仍有改进的余地。CENTERA 阀门(Edwards Lifesciences, Irvine, California) 是 Edwards 系列的新一代自扩展 (SE)-THV,它融合了一些有趣的技术优势 (3)。支架框架有 3 种尺寸(腰部水平为 23、26 和 29 毫米),并在环形位置包含 3 个牛心包瓣叶。镍钛诺框架的形状和设计有助于瓣膜在瓣环内的居中和就位。此外,其较短的长度(与其他 SE 系统相比是最短的框架)确保了升主动脉的有限伸展和扩张的流入部分向左心室流出道 (LVOT) 的最小突出。阀门预先连接到电动输送系统(与 14-F 可扩展 和 29 毫米在腰部)并在环形位置包含 3 个牛心包小叶。镍钛诺框架的形状和设计有助于瓣膜在瓣环内的居中和就位。此外,其较短的长度(与其他 SE 系统相比是最短的框架)确保了升主动脉的有限伸展和扩张的流入部分向左心室流出道 (LVOT) 的最小突出。阀门预先连接到电动输送系统(与 14-F 可扩展 和 29 毫米在腰部)并在环形位置包含 3 个牛心包小叶。镍钛诺框架的形状和设计有助于瓣膜在瓣环内的居中和就位。此外,其较短的长度(与其他 SE 系统相比是最短的框架)确保了升主动脉的有限伸展和扩张的流入部分向左心室流出道 (LVOT) 的最小突出。阀门预先连接到电动输送系统(与 14-F 可扩展 其较短的长度(与其他 SE 系统相比是最短的框架)确保了升主动脉的有限伸展和扩张的流入部分向左心室流出道 (LVOT) 的最小突出。阀门预先连接到电动输送系统(与 14-F 可扩展 其较短的长度(与其他 SE 系统相比是最短的框架)确保了升主动脉的有限伸展和扩张的流入部分向左心室流出道 (LVOT) 的最小突出。阀门预先连接到电动输送系统(与 14-F 可扩展
更新日期:2017-12-01
down
wechat
bug